Search Articles — Sudonull

https://sudonull.com/solod-go-without-gc-with-compilation-to-c

Solod is a subset of Go with manual memory management, compiles to C11. Benchmarks, features, integration with C. Ideal for systems programming. Learn more.

https://sudonull.com/asmx-raptor-native-assembler-and-strict-typing-in-system-programming

AsmX Raptor integrates assembler into the compiler's AST, offering unprecedented control and security for systems developers. Learn about the new compilation pipeline, evolution of the type system, and support for version-independent Linux kernel modules.

https://sudonull.com/renga-api-and-ai-agents-for-bim

Integrate AI with Renga API via COM and Python. Automate plugins, STDL families. Comparison with Revit, code examples. Start development without compilation.

https://sudonull.com/kite-language-in-c-for-termux-and-android

Learn how to implement the KITE language interpreter in C: lexer, parser, AST, refcounting. Compilation in Termux, OOP, closures. Sources are open — study and improve them.

https://sudonull.com/dart-backend-benchmarks-and-memory-issues

Dart vs Node.js benchmarks: latency 9.5s, memory not returned in K8s. Why migration failed, ecosystem and GC for Flutter. Read raw results.

https://ymaho.com/fda-approval-of-combination-immunotherapy-for-bladder-cancer-durvalumab-bcg

FDA approved durvalumab with BCG for high-risk NMIBC. POTOMAC data: 32% risk reduction. Analysis of efficacy, toxicity, and consequences of BCG shortage. Learn more.

https://ymaho.com/orphan-status-of-combination-for-lung-cancer-treatment-new-ema-approach

European Commission granted orphan status to Zepzelca combination with atezolizumab for lung cancer. Learn how EMA reform changes rules for SCLC and who benefits from this decision. Detailed analysis.

https://ymaho.com/new-drug-combination-for-lung-cancer-therapy-european-approval

European Commission approved Zepzelca and atezolizumab combination for aggressive lung cancer. 27% reduction in risk of death. Learn details about the new standard of therapy.

https://ymaho.com/fda-approved-differin-epiduo-over-the-counter-combination-gel-for-acne

Learn how FDA approved the first over-the-counter gel Differin Epiduo (adapalene+benzoyl peroxide) for treating acne in adolescents and adults. Price, benefits, risks — read in the analysis.

https://ymaho.com/fda-approved-imfinzi-first-immunotherapeutic-combination-for-bladder-cancer

FDA approved Imfinzi (durvalumab) + BCG for high-risk non-muscle-invasive bladder cancer. 32% reduction in recurrence risk. Learn about the breakthrough in oncourology.

https://ymaho.com/deepdrug-ai-model-predicts-drug-interactions-12-thousand-dangerous-combinations

DeepDrug found 12 thousand dangerous drug combinations. How AI is changing pharmacology and why it threatens pharma giants? Detailed analysis.

https://ymaho.com/hepatitis-c-cocktail-cure-in-7-8-weeks

The combination of bemnifosbuvir and ruzasvir reduces the treatment course for hepatitis C from 12 to 7–8 weeks. Learn about trial results and benefits of the new regimen.

https://ymaho.com/scandinavian-protocol-magnesium-baths-and-forest-saunas

How the combination of floating with magnesium and forest sauna reduces cortisol by 32% and changes the wellness market. Find out the session price and risks of the new trend.

https://ymaho.com/kras-g12c-colorectal-cancer-sotorasib-panitumumab-breakthrough

CodeBreak300 phase 3: Lumakras and Vectibix combination increased progression-free survival by 3 months. Treatment of KRAS G12C metastases approved. How dual blockade breaks 40-year resistance.

https://ymaho.com/green-buckwheat-and-fermented-chia-seeds-superfoods-of-summer-2026

University of Toronto study: the combination increases magnesium bioavailability by 71% and reduces sugar cravings by 40%. Who benefits and who loses? Read the analysis.